Cancer and the Peutz-Jeghers syndrome

A D SPIEGELMAN, V MURDAY, AND R K S PHILLIPS

From St Mark’s Hospital, London and the Professorial Surgical Unit, St Bartholomew’s Hospital, London

SUMMARY Among 72 patients with the Peutz-Jeghers syndrome malignant tumours have developed in 16 (22%) of whom all but one have died. There were nine gastrointestinal and seven non-gastrointestinal tumours. The relative risks of death from gastrointestinal cancer and all cancers were 13 (95% CI 2.7–38.1) and 9 (95% CI 4.2–17.3) respectively. The chance of dying of cancer by the age of 57 was 48%. There is evidence for a hamartoma/carcinoma sequence in the Peutz-Jeghers syndrome, suggesting that the gene locus involved is relevant to the development of malignancy in general.

The Peutz-Jeghers syndrome is an autosomal dominant condition characterised by mucocutaneous pigmentation and gastrointestinal hamartomas. Hamartomas are not generally regarded to be pre-malignant, but in the Peutz-Jeghers syndrome a number of authors have found an excessive rate of gastrointestinal malignancy. Some of this excess may have been caused by overdiagnosis of malignancy in Peutz-Jeghers polyposis. This can arise when epithelial displacement beneath the muscularis propria, which is quite commonly seen in the Peutz-Jeghers syndrome, is reported as malignant invasion. In 1987, Giardiello et al reported 31 patients with the Peutz-Jeghers syndrome in the United States. They confirmed an excessive risk of gastrointestinal malignancy. In addition, they found an excess of malignancies at a number of other sites. Others have reported associations with bilateral breast cancer, ovarian sex cord tumours (with and without precocious puberty), adenoma malignum—which is a rare form of cervical cancer—and feminising Sertoli cell tumours in pre-pubertal boys.

In the gastrointestinal tract malignancy could arise as a consequence of a hamartoma/dysplasia/carcinoma sequence, or may arise in adjacent tissue.

We studied Peutz-Jeghers patients registered with the St Mark’s Polyposis Registry to assess the incidence, site and outcome of neoplasia, with a view to establishing guidelines for their follow up.

Methods

PATIENTS The St Mark’s Polyposis Registry has 72 patients (39 women) registered with the Peutz-Jeghers syndrome of whom 17 are under regular review at St Mark’s Hospital. Registration involved review of the clinical information and of the pathology in all cases. Of the patients registered, we have identified six, three of whom have been previously reported, because they had developed cancer. We have excluded these six patients from the long-term risk analysis in order to minimise selection bias in our estimate of the cancer risk in this syndrome. Questionnaires were sent to the remaining patients who were not under follow up at this hospital or were administered in outpatients to those that were. Patients were asked to provide details of serious illness or tumours occurring in themselves or in relatives. The relative risk of developing cancer and cumulative survival were calculated using the life table method. Relative risk was defined as the ratio of the observed risk in the study group compared with that expected from their age and sex matched equivalents in the overall population of England and Wales. All registered patients participated in the study.

Results Malignant tumours have developed in 16 patients (22%, nine women). Of these cancers, 10 were gastrointestinal (one patient had two cancers) and seven developed outside the gastrointestinal tract.
Cancer and the Peutz-Jeghers syndrome

Table 1  Malignant tumours encountered

<table>
<thead>
<tr>
<th>Gastrointestinal</th>
<th>Non-gastrointestinal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stomach</td>
<td>3 (f30, m31, 38)</td>
</tr>
<tr>
<td>Duodenum</td>
<td>1 (f57)</td>
</tr>
<tr>
<td>Duodeno-jejunal</td>
<td>2 (f28, m38)</td>
</tr>
<tr>
<td>Jejunum</td>
<td>1 (f26)</td>
</tr>
<tr>
<td>Colon</td>
<td>2 (f26, m40)</td>
</tr>
<tr>
<td>Pancreas</td>
<td>1 (m34)</td>
</tr>
</tbody>
</table>

(95% interval 26–38) (Table 1). The presence of carcinoma within a hamartoma was reported in four of the eight patients where the cancer arose within the intestinal lumen, and may have been present in a fifth patient. With the exception of one woman patient who developed a basal cell carcinoma on the face at the age of 39, all tumours were lethal, these patients dying at an average age of 38 years. Calculating years at risk using the life table method for 66 patients, the relative risk of death from gastrointestinal cancer was 13 (95% CI 2.7–38.1) and the relative risk of dying from any malignancy was nine (95% CI 4.2–17.3) (Table 2). The chance of dying of cancer by the age of 57 was 48%, and the chance of dying of any cause was 57% (Figure).

Table 2  Relative risks for cancer death

<table>
<thead>
<tr>
<th>Gastrointestinal cancer</th>
<th>All cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Years at risk</td>
<td>1992</td>
</tr>
<tr>
<td>Unexpected deaths</td>
<td>E 0.23</td>
</tr>
<tr>
<td>Observed deaths</td>
<td>O 3</td>
</tr>
<tr>
<td>Ratio</td>
<td>O/E 13</td>
</tr>
</tbody>
</table>

(Excludes six patients from Table 1 (see text))

Discussion

There is a significantly increased risk that patients with Peutz-Jeghers syndrome will die of cancer at a young age. Rare cancers occur more commonly in Peutz-Jeghers patients. In addition, common cancers such as lung, breast, and colon, appear at a younger age than expected in the general population. Review of the literature suggests that bilateral breast cancer, 5 gynaecological malignancies 11, 12 and testicular cancer in prepubertal boys 13, 14 are particularly common. What can be done to prevent death from extra-intestinal cancers in these patients?

In the United Kingdom, screening mammography is available to women over 50 years old. Women at high risk because of genetic factors should have this service made available annually from the age of 40, with a base line mammogram at the age of 25 years. Clinical review should then be yearly. Women with the Peutz-Jeghers syndrome should perhaps be included in this group, and in addition have annual pelvic ultrasound and cervical smears.

Both male and female patients should be encouraged to carry out self examination, and doctors should regard abnormal findings with a high index of suspicion.

The management of the risk of gastrointestinal malignancy tics in closely with the management of polyps in general. A Peutz-Jeghers polyp seen through the intestinal wall at laparotomy shows serosal puckering, probably as a result of the already mentioned epithelial displacement that sometimes leads to confusion over malignancy. 10 These polyps are broadly based and deeply adherent, which makes endoscopic removal difficult, particularly when the polyps are large. It is important when operating on patients with the Peutz-Jeghers syndrome to completely clear the intestine of polyps. This can be achieved by panintestinal endoscopy with the colonoscope passed both from the mouth and from the anus while the abdomen is open. Small polyps can be snared, while larger ones will need an enterotomy for their removal. Thereafter, a policy of two yearly upper gastrointestinal endoscopy and colonoscopy should allow removal of polyps before their size mitigates against this. Polyps outside the reach of endoscopes pose a particular problem. Certainly a small bowel enema will show large ones. We believe that the risk of malignancy should dictate a more aggressive management than heretofore and advocate two yearly small bowel follow through examinations, as proposed by Williams et al in 1982. 20 Patients with polyps greater than 1.5 cm diameter, or with smaller polyps but abdominal pain as well, should be advised to undergo laparotomy in the way described above. We hope that thorough attention to the removal of all
small polyps at the time of laparotomy will mean that operations do not have to be undertaken too frequently, although this remains to be seen.

The gene in Peutz-Jeghers syndrome appears to control growth and differentiation in the gastrointestinal tract, as shown by the development of hamartomas. In addition, there is clearly some evidence for a hamartoma/carcinoma sequence, and this has already been suggested for patients with juvenile polyposis.\(^2\) The gene is also expressed in other tissues, as shown by the abnormal freckling. The generally increased risk of cancer at a number of other sites suggests that the gene locus involved may be of importance to cancer development in general.

We are grateful to the St Mark’s Polyposis Registry, and in particular to Dr H J R Bussey for his meticulous record keeping over the years. Mr Spigelman is supported by the St Mark’s Research Foundation, and Dr V Murday, Senior Registrar, Genetics, Royal Free Hospital Medical School, by the Imperial Cancer Research Fund.

References


Cancer and the Peutz-Jeghers syndrome.

A D Spigelman, V Murday and R K Phillips

Gut 1989 30: 1588-1590
doi: 10.1136/gut.30.11.1588

Updated information and services can be found at:
http://gut.bmj.com/content/30/11/1588

Email alerting service

These include:
Receive free email alerts when new articles cite this article.
Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Cancer: small intestine (189)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/